PolyPid (PYPD, Financial), a clinical-stage biopharmaceutical company, has been given a "Buy" rating by HC Wainwright & Co. This positive outlook is accompanied by a price target announcement of $11.00 USD, as stated by analyst Brandon Folkes.
This latest evaluation marks the first time HC Wainwright & Co. has assessed PolyPid (PYPD, Financial), with no prior ratings available for the company. As of June 2, 2025, the new price target suggests a promising potential for stock value appreciation based on the company's ongoing developments.
Investors closely monitoring PolyPid (PYPD, Financial) will find this rating noteworthy as it indicates a favorable position for the company's stock in the market. As PolyPid continues its operations, market participants will likely watch for further updates that could impact the stock's trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $11.33 with a high estimate of $13.00 and a low estimate of $10.00. The average target implies an upside of 309.15% from the current price of $2.77. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
